Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
NCT07687212Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Jul 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
A Phase 2 trial of henagliflozin in heart failure with preserved ejection fraction (HFpEF), sponsored by Xijing Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT07687212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07687212.